{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:12:29Z","timestamp":1788901949430,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001286","name":"Pan-Massachusetts Challenge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtho.2026.104136","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:47:44Z","timestamp":1785944864000},"page":"104136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Brief Report"],"prefix":"10.1016","author":[{"given":"Federica","family":"Pecci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Gariazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Garbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Paoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Rossato de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Aldea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao V.","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Canty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bruschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gusev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narjust","family":"Florez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Christiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Rodig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi A.","family":"J\u00e4nne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Ricciuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.104136_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtho.2026.104136_bib2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.104136_bib3","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1158\/1078-0432.CCR-24-2990","article-title":"Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer","volume":"31","author":"Pecci","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.104136_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2668","article-title":"Late-onset immune-related adverse events after immune checkpoint inhibitor therapy","volume":"8","author":"Durbin","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtho.2026.104136_bib5","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jamaoncol.2019.3221","article-title":"Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden","volume":"5","author":"Bomze","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2026.104136_bib6","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","article-title":"Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels","volume":"8","author":"Ricciuti","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2026.104136_bib7","article-title":"Immunoprofiling at an institutional scale reveals that high numbers of intratumoral CD8+ and PD-1+ cells predict superior patient survival across major cancer types independent of major risk factors","volume":"9","author":"Alessi","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2026.104136_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102418","article-title":"Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment","author":"Lindsay","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jtho.2026.104136_bib9","article-title":"Association of baseline tumor-specific neoantigens and CD8+ T-cell infiltration with immune-related adverse events secondary to immune checkpoint inhibitors","volume":"8","author":"Kerepesi","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2026.104136_bib10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/cancers15030649","article-title":"Immune-related thyroiditis in patients with advanced lung cancer treated with immune checkpoint inhibitors: imaging features and clinical implications","volume":"15","author":"Park","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2026.104136_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180076","article-title":"Mechanisms underlying sex differences in autoimmunity","volume":"134","author":"Fairweather","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtho.2026.104136_bib12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2026.104136_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108270","article-title":"Autoimmunity in women: an eXamination of eXisting models","volume":"210","author":"Yuen","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jtho.2026.104136_bib14","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.3390\/cancers14153568","article-title":"Positive correlation of peripheral CD8+ T lymphocytes with immune-related adverse events and combinational prognostic value in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors","volume":"14","author":"Wu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2026.104136_bib15","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.104136_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426005897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426005897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:49:51Z","timestamp":1788900591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426005897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":16,"alternative-id":["S1556086426005897"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104136","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Brief Report","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"104136"}}